Sydney-based Omniscient Neurotechnology has received 510 (k) clearance from the US FDA for its brain mapping software.
WHAT IT’S ABOUT
Quicktome is a digital brain mapping platform that enables clinicians to visualize a patient’s brain networks that are responsible for complex functions such as language, movement, and cognition.
With intuitive browser interfaces, the platform analyzes millions of data points from a patient’s MRI. Cloud computing is then used to process big data.
WHY IT IS IMPORTANT
Quicktome integrates Connectomics, or the study of brain connections, into routine neurosurgical planning.
The platform was developed by neurosurgeons and data scientists to help clinicians make informed decisions. It also reduces uncertainty by providing insight into a patient before and during life-changing brain surgery. The company says its solution can derive insights into various brain-related diseases such as Alzheimer’s, depression, chronic pain, and brain tumors.
In addition, the platform enables multidisciplinary collaboration in hospitals.
Quicktome also recently received approvals from Health Canada and the Australian Therapeutic Goods Administration.
THE BIGGER TREND
As recently as Monday, Omniscient Neurotechnology closed a Series B funding round that raised A $ 40 million ($ 29.4 million) from investors including Gina Rinehart, executive chairman of Australian mining company Hancock Prospecting and well-known fund manager Will Vicars .
The company will use its new funds to advance research and develop more medical devices and research solutions. The company is also committed to expanding its science, engineering, and sales teams around the world. The funds will be used to bring Quicktome and Infinitome, another research platform, to other markets.
ON THE RECORD
“Until now, the tools that neurosurgeons have relied on have not been able to cope with the complexity of the brain. Quicktome breaks information into actionable insights to determine the impact of each incision on the patient. Physicians have relied on this technology since it was approved. “This is a significant milestone for Omniscient and, more importantly, a new era in neurosurgery for patients and physicians,” said Stephen Scheeler, CEO of Omniscient Neurotechnology.
“Big data changes everything we know about the brain. Modern neuroscience has shown that we are our brain networks that control everything from movement to language. Understanding how the brain is connected and what those connections mean will dramatically help us improve healthcare, starting with neurosurgery, ”commented Stephane Doyen, the company’s chief data officer.